Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis and clinical assessment: an updated meta-analysis of randomized trials

Han et al., Journal of Thoracic Disease, doi:10.21037/jtd-23-1043
May 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Meta analysis of 9 RCTs with 7,825 participants showing significantly lower COVID-19 cases with HCQ prophylaxis. Authors only cover the period until January 2022. The very long publication delay may be due to the reported difficulty publishing positive results. Additional more recent studies further confirm efficacy. Adverse events were increased, however authors do not distinguish serious and minor adverse events. The primary contributor to the increased adverse events is Mitjà et al. which reported very high gastrointestinal side effects with treatment, which is not seen in other major trials. Mitjà et al. do not specify whether HCQ was administered with food, which is known to reduce gastrointestinal side effects.
8 meta analyses show significant improvements with hydroxychloroquine for mortality2-5, hospitalization2, recovery6, combined death/hospitalization/cases7, and cases8,9.
Currently there are 39 HCQ for COVID-19 early treatment studies, showing 76% lower mortality [61‑85%], 67% lower ventilation [-710‑99%], 31% lower ICU admission [1‑53%], and 41% lower hospitalization [28‑51%].
Han et al., 31 May 2024, peer-reviewed, 3 authors. Contact: 840466694@qq.com.
This PaperHCQAll
The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis and clinical assessment: an updated meta-analysis of randomized trials
Xudong Han, Wei Shi, MS. Ya Yang
Journal of Thoracic Disease, doi:10.21037/jtd-23-1043
Background: Coronavirus disease 2019 (COVID-19), a disease that affected tens of millions of people, upended the lives of countless individuals around the globe. The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) were the most frequently cited as potential treatments and preventatives against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The primary aim of this investigation was to scrutinize the effectiveness and safety of HCQ for COVID-19 prevention and to present powerful evidence and reference for clinical practice. Methods: PubMed, Ovid and the Cochrane COVID-19 Register of Controlled Trials (CENTRAL) were systematically searched from inception to January 31, 2022. Randomized controlled trials (RCTs) trials that included participants who were SARS-CoV-2 negative at the time of registration were enrolled in this metaanalysis. The intervention group took HCQ or CQ orally. The control group was not blinded by quinine or placebo. Pooled relative risk (RR) of SARS-CoV-2 infection, mortality, hospitalization, adverse events, and compliance were calculated. The software tools utilized for statistical analyses were Stata 14 and Review Manager 5.3. Results: A total of 9 studies including 7,825 participants were enrolled. Bias of individual studies were assessed as low risk. The pooled RR for SARS-CoV-2 infection was 0.75 [95% confidence interval (CI): 0.68-0.83] (z=-4.01, P<0.0001; I 2 =11%). The pooled RR for hospitalization was 0.72 (95% CI: 0.35-1.50) (z=0.87, P=0.39; I 2 =0.0%). The pooled RR for mortality and adverse events were 3.26 (95% CI: 0.13-79.74) (z=0.72, P=0.47; I 2 =0.0%) and 1.90 (95% CI: 1.20-3.02) (z=2.73, P=0.0063; I 2 =94%). Conclusions: Results of this meta-analysis indicated significant impact of HCQ on SARS-CoV-2 infection with higher risk of adverse events. These findings must be considered with caution, and further research is necessary to delineate the specific circumstances where HCQ may be effective for COVID-19 prevention.
Conflicts of Interest
References
Abella, Jolkovsky, Biney, Efficacy and Safety of Hydroxychloroquine vs Placebo for Preexposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial, JAMA Intern Med
Ather, Patel, Ruparel, Coronavirus Disease 19 (COVID-19): Implications for Clinical Dental Care, J Endod
Barnabas, Brown, Bershteyn, Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial, Ann Intern Med
Bartoszko, Siemieniuk, Kum, Prophylaxis against covid-19: living systematic review and network meta-analysis, BMJ
Boulware, Pullen, Bangdiwala, A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med
Cortegiani, Ingoglia, Ippolito, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J Crit Care
Cumpston, Li, Page, Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions, Cochrane Database Syst Rev
Deming, Chen, COVID-19 and Lessons to Be Learned from Prior Coronavirus Outbreaks, Ann Am Thorac Soc
Dersimonian, Laird, Meta-analysis in clinical trials revisited, Contemp Clin Trials
Dersimonian, Laird, Meta-analysis in clinical trials, Control Clin Trials
Dhibar, Arora, Kakkar, Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study, Int J Antimicrob Agents
Egger, Smith, Schneider, Bias in meta-analysis detected by a simple, graphical test, BMJ
Faraone, Qu, Goodarzi, Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3, Emerg Microbes Infect
García-Albéniz, Amo, Polo, Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19, Eur J Epidemiol
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Grau-Pujol, Camprubí-Ferrer, Marti-Soler, Et, hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial, J Thorac Dis, doi:10.21037/jtd-23-1043al.Pre-exposureprophylaxiswith
Higgins, Altman, Gøtzsche, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ
Higgins, Thompson, Deeks, Measuring inconsistency in meta-analyses, BMJ
Hong, Friedland, Hu, Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials, BMJ Open
Jorge, Ung, Young, Hydroxychloroquine retinopathy -implications of research advances for rheumatology care, Nat Rev Rheumatol
Keyaerts, Vijgen, Maes, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem Biophys Res Commun
Kumar, Khodor, Pathophysiology and treatment strategies for COVID-19, J Transl Med
Lewis, Chaudhuri, Alshamsi, The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials, PLoS One
Lu, Zhao, Li, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet
Mavridis, Salanti, How to assess publication bias: funnel plot, trim-and-fill method and selection models, Evid Based Ment Health
Mckinnon, Wang, Zervos, Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study, Int J Infect Dis
Mitjà, Corbacho-Monné, Ubals, A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19, N Engl J Med
Moher, Liberati, Tetzlaff, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Int J Surg
Rajasingham, Bangdiwala, Nicol, Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial, Clin Infect Dis
Rodrigo, Fernando, Rajapakse, Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review, Clin Microbiol Infect
Salian, Wright, Vedell, COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies, Mol Pharm
Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol
Seet, Quek, Ooi, Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial, Int J Infect Dis
Shetty, Namachivayam, Evidence for Chloroquine/ Hydroxychloroquine in the Treatment of COVID-19, Indian J Crit Care Med
Singh, Chauhan, Kakkar, Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead, Eur J Pharmacol
Sterne, Savović, Page, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ
Tindale, Stockdale, Coombe, Evidence for transmission of COVID-19 prior to symptom onset, Elife
Vincent, Bergeron, Benjannet, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Weston, Coleman, Haupt, Broad Anticoronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo, J Virol
Yao, Ye, Zhang, In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zeouk, Bekhti, Lorenzo-Morales, From Wuhan to COVID-19 Pandemic: An Up-to-Date Review of Its Pathogenesis, Potential Therapeutics, and Recent Advances, Microorganisms
Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemother
Zhou, Verweij, Bijlsma, Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis, BMJ Open Respir Res
{ 'indexed': {'date-parts': [[2024, 6, 1]], 'date-time': '2024-06-01T00:28:10Z', 'timestamp': 1717201690423}, 'reference-count': 0, 'publisher': 'AME Publishing Company', 'issue': '5', 'content-domain': {'domain': ['amegroups.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 5]]}, 'DOI': '10.21037/jtd-23-1043', 'type': 'journal-article', 'created': {'date-parts': [[2024, 5, 31]], 'date-time': '2024-05-31T01:58:33Z', 'timestamp': 1717120713000}, 'page': '2983-2993', 'update-policy': 'http://dx.doi.org/10.21037/ame_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis and clinical assessment: ' 'an updated meta-analysis of randomized trials', 'prefix': '10.21037', 'volume': '16', 'author': [ {'given': 'Xudong', 'family': 'Han', 'sequence': 'first', 'affiliation': []}, {'given': 'Wei', 'family': 'Shi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ya', 'family': 'Yang', 'sequence': 'additional', 'affiliation': []}], 'member': '8611', 'published-online': {'date-parts': [[2024, 5]]}, 'container-title': 'Journal of Thoracic Disease', 'original-title': [], 'link': [ { 'URL': 'https://jtd.amegroups.com/article/download/86436/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 5, 31]], 'date-time': '2024-05-31T01:59:12Z', 'timestamp': 1717120752000}, 'score': 1, 'resource': {'primary': {'URL': 'https://jtd.amegroups.com/article/view/86436/html'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 5]]}, 'references-count': 0, 'journal-issue': { 'issue': '5', 'published-online': {'date-parts': [[2024, 5]]}, 'published-print': {'date-parts': [[2024, 5]]}}, 'URL': 'http://dx.doi.org/10.21037/jtd-23-1043', 'relation': {}, 'ISSN': ['2072-1439', '2077-6624'], 'subject': [], 'container-title-short': 'J Thorac Dis', 'published': {'date-parts': [[2024, 5]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit